Background/Aims: The immune response to influenza vaccine may be influenced by many factors, e.g. age, comorbidities or inflammation, and iron status. Methods: We studied the vaccine-induced production of hemagglutination-inhibition antibodies (HI) in 133 hemodialysis patients (HD) and 40 controls. To identify variables associated with the immune response, uni-and multivariate regression analyses were performed with seroconversion in HI titers as a dependent variable, with demographics, comorbidities, previous vaccination, inflammation, and iron status as independent variables. Results: Seroconversion rates were lower in HD than in controls [43% versus 73% (H1N1 strain; p < 0.05); 43% versus 53% (H3N2; P=NS); 36% versus 62% (B; p < 0.05)]. In both HD and control groups, the predictors of the inferior HI production were pre-vaccination seroprotection, vaccination in the previous season, and old age. We did not find associations between seroconversion rates and inflammation and iron status in the studied populations. This was also true for a subanalysis of patients without pre-vaccination seroprotection. Conclusion: The influenza vaccine-induced antibody production was lower in HD than in controls and was independent of inflammation and iron status in both groups. Besides dependence on dialysis, the variables associated with inferior seroconversion rates included pre-vaccination seroprotection, previous vaccination, and old age.
Previous Vaccination and Age are More Important Predictors of Immune Response to Influenza Vaccine than Inflammation and Iron Status in Dialysis Patients
Jaromír
Introduction
Influenza is a serious respiratory infection with a major health and socio-economic impact. Each year, influenza causes a substantial number of hospitalizations and deaths [1, 2] . The estimated global number of deaths associated with the 2009 pandemic influenza A H1N1 during the first 12 months of virus circulation was about half of a million [3] . Patients with chronic renal failure are considered a risk population, and European and global authorities recommend their regular vaccination [4] [5] [6] . An influenza vaccine is likely to reduce the risk of hospitalization and mortality in maintenance hemodialysis (HD) patients [7] . However, according to some analyzes, a real protective effect of influenza vaccination in HD patients is disputable [8] . The intensity of antibody response is variable and may be affected by age, genetic factors, with factors associated with renal failure and dialysis therapy coming into play in HD [9, 10] . Immune reactivity may be affected by inflammation and changes in iron metabolism [11] . Both iron deficiency and iron overload are associated with impaired immune reactivity [12] . In our previous study, very high levels of ferritin were associated with low production of hemagglutination-inhibition antibodies (HI) [13] . The aim of the present study was to test, in a larger population of HD and controls without renal dysfunction, the relationship between the immune response to vaccine and markers of inflammation, iron status, demographic factors, and comorbidities.
Material and Methods

Study populations
The study was conducted in November and December 2009 and included HD patients from three dialysis centers in Plzeň and a control group that consisted of pensioners and university personnel living in the same geographical area (Plzeň region, Czech Republic). All participants were examined and vaccinated in parallel and were in stable clinical condition. Individuals with infection (C-reactive protein >30 mg/L), malnutrition (albumin <35 g/L), hepatitis B or C, malignancy or a history of severe acute infection within the last three months were excluded.
Patients were dialyzed for 4 h/session (4.0-5.0), 3 times a week, using ultrapure dialysis fluid and highflux polysulfone dialyzers. Their Kt/V was 1.60 (1.38-1.71). Causes of renal failure included nephrosclerosis (n = 25), tubulointerstitial nephritis (n = 27), glomerulonephritis (n = 21), polycystic kidney disease (n = 7), diabetic nephropathy (n = 49), and renal tumor treated with bilateral nephrectomy more than two years previously (n = 4). HD patients were anuric or their residual renal function was negligible 1 (0-2) mL/min (the average of renal urea and creatinine clearance). Control subjects had an eGFR of 72 (61-77) mL/min (CKD-EPI creatinine 2009 equation). HD patients were treated with erythropoietin (EPO) to keep their hemoglobin at 100-120 g/L. Weekly doses of intravenous iron (sodium iron gluconate, Fe iv ) were set according to the results of routine iron status determinations (measured at least every 3 months) to keep transferrin saturation >20% and ferritin >300 μg/L. Two weeks before the commencement of the study, patients were not given any intravenous iron to prevent false results of laboratory tests of iron metabolism. The Ethics Committee of the University Hospital in Plzeň approved the study and all participants gave their written consent to participate.
Biochemical measurements
Blood samples were taken under identical conditions after an overnight fast. In HD patients, the samples were taken before the first dialysis of the week. The blood samples for biochemical tests were transported to the laboratory within 30 min and processed immediately thereafter using standard analytical techniques (blood hemoglobin, serum albumin, C-reactive protein, transferrin, iron, transferrin saturation, soluble transferrin receptor, and ferritin) or stored at -80 °C (hepcidin and interleukin 6, as the analysis had to be postponed for technical reasons). Interleukin 6 was measured by an ELISA kit (R&D Systems, Minneapolis, MN, USA) and hepcidin by an ELISA kit (Bachem Ltd., St. Helens, Merseyside, UK) using a Nexgen Four analyzer (Adaltis, Rome, Italy). All samples were analyzed in parallel. Pairs of blood samples were taken before and 4 weeks after vaccination to determine baseline and post-vaccination HI titers. Sera of HD patients and controls were stored at -20°C and processed simultaneously. HI titers against the prototype vaccine strains were measured by a standard HI assay. Medicinal Products for assessment of vaccine in groups of subjects aged over 60 were as follows: proportion of subjects with seroconversion >30%, proportion of subjects with seroprotection >60%, factor increase in geometric mean titer >2.0, seroprotection corresponds to HI titers ≥40, seroconversion corresponds to a negative pre-vaccination HI titer (HI <10) and a post-vaccination HI titer of ≥40 or a ≥4 fold increase in HI titer after vaccination, factor increase in geometric mean titer is the ratio of geometric means of post-/pre -vaccination HI titers [14] .
Vaccine administration, definitions and outcome measures
The outcome measures were: 1) to compare the production of HI antibodies in HD patients and controls; 2) to determine whether markers of inflammation, iron status, demographic characteristics, and comorbidities are associated with impaired immune response in HD patients and controls.
Statistics
Continuous variables are expressed as median (interquartile range). Data was checked for normality graphically (histograms) and if needed, formal test (Shapiro-Wilk) was used. Differences between groups were analyzed using the Mann-Whitney test. Proportions are expressed in percentage or percentage (95% confidence interval) and were analyzed using the χ 2 test. To identify determinants of seroconversion, uniand multivariate ordered logistic regression was performed. Variables considered for analysis included age, gender, hypertension, diabetes, cardiovascular disease, dialysis vintage, presence of pre-vaccination seroprotection (SP pre ), vaccination in the previous season, EPO and Fe iv doses, blood hemoglobin, serum iron, transferrin, transferrin saturation, ferritin, soluble transferrin receptors, hepcidin, albumin, interleukin 6, and C-reactive protein. Variables associated with seroconversion to at least two vaccine strains (P <0.2) in univariate analysis were added to the multivariate model. Given that pre-vaccination seroprotection (SP pre ) proved to be an important negative determinant of seroconversion, a separate subanalysis of patients without SP pre was performed. All P-values were two-tailed and values <0.05 were considered significant, with the exception of the selected variables for multivariate regression as described above. All analyses were carried out using R 3.2.0 software [R: A language and environment for statistical computing, Vienna, Austria; http://www.R-project.org/].
Results
Characteristics of the 133 HD patients and 40 controls are summarized in Table 1 . HD patients fared significantly worse in most of the biochemical variables. However, the absolute values of those indicators and the clinical status excluded severe infection, malnutrition, anemia, iron deficiency or iron overload in both the HD and control groups.
Seroconversion rates against the H1N1 and B strains were significantly higher in the control group than in HD patients. Better production of HI in controls was also documented by factor increase in geometric mean HI titers to the H1N1 strain. A trend toward an inferior immune response in HD patients compared to controls was apparent in all measured serological variables. The data are summarized in Table 2 .
Subsequently, we studied the associations between seroconversion to each of the three vaccine strains and demographic and biochemical variables in both HD patients and controls. Factors considered for the analysis are presented in Table 1 . Regression models were built separately for each group (HD patients and controls). To select important determinants and improve the robustness of the analysis, the variables associated with seroconversion to at least two vaccine strains (P <0.2) in univariate analysis were added to the multivariate model. Older age, SP pre , and influenza vaccination in the preceding season were predictors of decreased seroconversion rates in both the HD and control groups. None of the variables characterizing inflammation and iron status were associated with the seroconversion rates either in the HD or in the control group. To eliminate a potentially confounding factor, i.e. pre-vaccination seroprotection (SP pre ), a separate subanalysis of HD patients without SP pre was also status and demographics in both HD patients and in individuals without renal dysfunction. Seroconversion rates and some other serological characteristics of immune response were inferior in HD patients. Besides dependence on dialysis, the only determinants of lower seroconversion rates included older age, pre-vaccination seroprotective HI titers, and vaccination in the preceding season. This was true for both the HD and control groups. As age is known to affect the immune response, we enrolled age-matched volunteers [15] . Nursing home residents were intentionally not enrolled into our study, because this population is epidemiologically specific [16] . Most of control subjects were self-sufficient seniors and elderly hospital staff. As shown in Table 3 , the association between age and poor seroconversion was comparable in HD patients and controls.
Except for diabetics, who were fewer in the control group, the study groups were also comparable in terms of comorbidities. A higher percentage of diabetic patients should not seriously jeopardize the results, because the immune response to influenza vaccine in dia- Table 3 .
Discussion
To the best of our knowledge, this is the first controlled study examining associations between the immune response to an influenza vaccine and indicators of inflammation, iron betic patients does not seem to be impaired [17] . International guidelines and recent literature recommend influenza vaccination for all HD patients [18] . It is uncertain whether the positive effects of vaccination on morbidity and mortality imply true causality or only an association. A "positive effect of the vaccine" was described even in cases involving mismatch of vaccines, where the circulating strain differed from vaccine antigens [8] . Most of the previous studies have shown some degree of a reduced HI response in HD patients, usually inferior seroconversion rates. However, the percentage of HD patients who achieved seroprotection clearly supports vaccination in the HD population [19] [20] [21] [22] [23] . This also applies to vaccination against the novel 2009 influenza A (H1N1) pandemic virus [24] [25] [26] [27] .
In the present study, the intensity of immune response in HD patients was inferior to that of subjects without renal dysfunction. The rates of seroconversion in the A H1N1 and B strains were significantly lower in HD patients, while the trends toward a weakened response Table 3 . Determinants of seroconversion in all HD patients, in HD patients without pre-vaccination seroprotection and in controls no association with the inferior immune response was demonstrated. A state of chronic inflammation is closely linked to iron metabolism and this issue is particularly complex in HD patients [29] . A deteriorated immune response was found either in the presence of iron deficiency or iron overload [30] . While sufficient levels of iron are a prerequisite for response to erythropoietin, increased iron stores or administration of intravenous iron may impair cellular and humoral immunity [31, 32] . In the present study, the HD group showed moderate deviations in most variables of inflammation and iron metabolism in comparison with controls. Using univariate logistic regression, we tried to identify factors potentially associated (P<0.2) with seroconversion to at least two vaccine antigens; these variables were added to the multivariate model. However, none of the biochemical variables were associated with the inferior immune response. This was true for both HD patients and controls.
Pre-vaccination seroprotection (SP pre ) complicates the evaluation of the immune response and factors affecting antibody production [33] . The phenomenon of SP pre may be due either to the cross-reactivity after the contact with a similar virus in the past or to previous vaccinations. The proportions of SP pre subjects were comparable in our HD patients We also sought to identify the relationship between the antibody response to vaccine strains and markers of inflammation and iron metabolism. The adverse effect of inflammation on morbidity and mortality in the HD population is well known [28] . Although HD patients had significantly worse parameters of inflammation, i.e. 4 times higher C-reactive protein, 5 times higher interleukin 6 and ~20% lower serum albumin, and controls except for the B strain. To eliminate the confounding effect of SP pre , we studied patients without SP pre separately. No additional association was identified in this subanalysis (Table 3) .
Oversaturation of transferrin and high ferritin are known to impair the immune response [34, 35] . In our previous study, we showed that non-responders to an influenza vaccine had very high levels of ferritin compared to responders [median 821 μg/L (nonresponders) versus 571 (responders)] [12] . In the present study, we did not confirm an association of ferritin with the immune response. However, the median of ferritin levels in the HD group of the present study was lower (557 μg/L), most probably due to conservative supplementation of intravenous iron [12-week dose of 625 mg (median; previous study) versus 375 mg (this study)]. Scharpé et al. found a positive association between higher ferritin and the immune response in HD patients, but only to the H1N1 strain [33] . In Scharpé's study, the mean ferritin levels were 395 μg/L and even "the best responders" in the upper tertile had relatively low ferritin (>435 μg/L). In an uncontrolled study of 114 HD patients, Moon et al. did not demonstrate an association between the immune response and ferritin [36] . In Moon´s study, ferritin levels were about 160 μg/L, i.e. ~40% of values reported by Scharpé and only ~30% compared to our present study. This apparent heterogeneity of study populations makes interpretation of the effect of ferritin on the production of HI antibodies difficult. Our HD patients and controls did not experience severe iron overload so that our negative findings are not so surprising. The optimal level of ferritin is unknown and the potential role of this substance as an immune regulator or suppressor is a subject of debate [37] .
We also studied the effect of hepcidin, which is the regulator of iron metabolism, but also a possible new determinant of cardiovascular events and mortality in HD [38] . Hepcidin levels were approximately twice higher in HD than in controls, but we did not document any effect on the immune response. Soluble transferrin receptor (sTfR) can be useful in HD as an inflammation-independent marker of iron deficiency and EPO hyporesponsiveness [39, 40] . In our study, both HD and controls did not suffer from an iron deficiency, their sTrR levels were within the normal range, and sTrR was not associated with the inferior immune response.
Limitations
This study has some limitations which have to be pointed out. First, we cannot rule out that the lack of significance in associations between seroconversion and studied variables in HD and controls was due to the small sample size. This is the general problem of vaccination studies in HD, but our study is the second largest one. Second, the proportion of persons vaccinated in the preceding season was higher in HD group (53%) than in controls (33%), which could bias the differences in seroconversion rates.
Conclusions
In a multicenter controlled trial, we evaluated the production of HI antibodies after influenza vaccination in HD patients and in an appropriate control group without renal dysfunction. In both groups, we studied the effect of inflammation, iron status, demographics, and comorbidities on antibody production. We demonstrated a reduced immune response in HD patients. Besides dependence on dialysis, the strongest predictors of inferior production of HI antibodies included pre-vaccination seroprotection, vaccination in the previous season and older age. Our findings do not support the hypothesis of a negative impact of latent inflammation and impaired iron metabolism on immunity, at least in maintenance HD patients without active infection or iron overload.
